Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Recurrent Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT01463072
What this trial is testing

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced Breast CarcinomaMetastatic Breast CarcinomaRecurrent Breast Carcinoma+5 more
City of Hope Medical Center 40
Not applicableActive Not RecruitingNCT05931445
What this trial is testing

Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer

Who this might be right for
Breast CancerLung CancerColorectal Cancer+5 more
Comprehensive Support Project for Oncology Research 500
Testing effectiveness (Phase 2)Study completedNCT00020332
What this trial is testing

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Institute (NCI)
Post-approval studies (Phase 4)Study completedNCT02445586
What this trial is testing

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 52
Testing effectiveness (Phase 2)Study completedNCT00166543
What this trial is testing

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

Who this might be right for
Breast Cancer
SRI International 146
Large-scale testing (Phase 3)Looking for participantsNCT06926868
What this trial is testing

Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Who this might be right for
Breast Neoplasms
Bristol-Myers Squibb 600
Large-scale testing (Phase 3)UnknownNCT03966898
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 426
Early research (Phase 1)Study completedNCT00635596
What this trial is testing

Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer

Who this might be right for
Solid Tumors
Amgen Research (Munich) GmbH 65
Testing effectiveness (Phase 2)Study completedNCT00004925
What this trial is testing

Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00676663
What this trial is testing

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor-Positive Breast CancerBreast Cancer, Estrogen Receptor-Positive+1 more
Syndax Pharmaceuticals 130
Testing effectiveness (Phase 2)Study completedNCT03312738
What this trial is testing

Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 159
Testing effectiveness (Phase 2)Active Not RecruitingNCT02484404
What this trial is testing

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Who this might be right for
Colorectal NeoplasmsBreast Neoplasms
National Cancer Institute (NCI) 268
Testing effectiveness (Phase 2)Study completedNCT00258375
What this trial is testing

OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
NCIC Clinical Trials Group 15
Large-scale testing (Phase 3)Active Not RecruitingNCT05347134
What this trial is testing

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 254
Early research (Phase 1)Study completedNCT01209195
What this trial is testing

MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Who this might be right for
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,Primary Peritoneal Cancer or Endometrial CancerLocally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Merrimack Pharmaceuticals 41
Large-scale testing (Phase 3)Looking for participantsNCT06952803
What this trial is testing

Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Who this might be right for
Prostate Cancer
AstraZeneca 700
Early research (Phase 1)Study completedNCT01432886
What this trial is testing

Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Who this might be right for
Breast Cancer
Eisai Co., Ltd. 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07774624
What this trial is testing

Study of SKB103 in HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 140
Large-scale testing (Phase 3)Looking for participantsNCT06982521
What this trial is testing

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Who this might be right for
PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive Tumor+3 more
Relay Therapeutics, Inc. 540
Testing effectiveness (Phase 2)Ended earlyNCT01912963
What this trial is testing

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 32
Next Page